/PPBT
PPBT Stock - Purple Biotech Ltd.
Healthcare|BiotechnologyNASDAQ
$0.71-3.08%
$0.02 (-3.08%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.9
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.78
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PPBT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.70 – $0.71
TARGET (TP)$0.81
STOP LOSS$0.65
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.70
52W High$5.20
52W Low$0.53
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $195,804 | N/A | N/A | $1.00M |
| Gross Profit | $-186,000 | $-196 | $-120 | $-55 | $999,942 |
| Gross Margin | N/A | -0.1% | N/A | N/A | 100.0% |
| Operating Income | $-11,005,000 | $-22,271,000 | $-22,603,000 | $-17,934,000 | $-13,239,000 |
| Net Income | $-7,240,000 | $-19,880 | $-21,668,000 | $-18,384,000 | $-27,999,000 |
| Net Margin | N/A | -10.2% | N/A | N/A | -2799.9% |
| EPS | $-4.42 | $-0.16 | $-0.23 | $-0.21 | $-0.35 |
Company Overview
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PPBTBeat Rate
23%
Last 13 quarters
Avg Surprise
-366.6%
EPS vs Estimate
Beats / Misses
3/8
2 met exactly
Latest EPS
$-0.29
Q4 2025
EPS Surprise History
Q1 24
-88.2%
$-6.40vs$-3.40
Q2 24
0.0%
$-3.00vs$-3.00
Q3 24
-900.0%
$-1.60vs$-0.16
Q4 24
-14.2%
$-1.37vs$-1.20
Q1 25
-18.2%
$-0.26vs$-0.22
Q2 25
No data
Q3 25
-90.5%
$-0.40vs$-0.21
Q4 25
-11.5%
$-0.29vs$-0.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 19, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-0.34 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.26 | $-0.29 | -11.5% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.21 | $-0.40 | -90.5% | ✗ MISS |
Q2 2025 | May 21, 2025 | — | $-0.17 | — | — |
Q1 2025 | Mar 10, 2025 | $-0.22 | $-0.26 | -18.2% | ✗ MISS |
Q4 2024 | Nov 15, 2024 | $-1.20 | $-1.37 | -14.2% | ✗ MISS |
Q3 2024 | Aug 16, 2024 | $-0.16 | $-1.60 | -900.0% | ✗ MISS |
Q2 2024 | May 21, 2024 | $-3.00 | $-3.00 | 0.0% | = MET |
Q1 2024 | Mar 5, 2024 | $-3.40 | $-6.40 | -88.2% | ✗ MISS |
Q4 2023 | Nov 21, 2023 | $-4.40 | $-4.20 | +4.5% | ✓ BEAT |
Q3 2023 | Aug 22, 2023 | $-5.00 | $-4.60 | +8.0% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $-7.00 | $-4.20 | +40.0% | ✓ BEAT |
Q1 2023 | Feb 8, 2023 | $-6.00 | $-6.00 | 0.0% | = MET |
Q4 2022 | Nov 8, 2022 | $-0.21 | $-0.27 | -28.6% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | — | $-0.20 | — | — |
Q2 2022 | May 12, 2022 | — | $-0.41 | — | — |
Q1 2022 | Mar 1, 2022 | — | $-0.29 | — | — |
Q1 2022 | Feb 9, 2022 | — | $-0.18 | — | — |
Q3 2021 | Aug 5, 2021 | $-0.01 | $-0.38 | -3667.6% | ✗ MISS |
Latest News
Purple Biotech Announces New Preclinical Data From CAPTN-3 Tri-Specific Antibody Platform Presented At ESMO IO Congress 2025
📈 PositiveBenzinga•Dec 11, 2025, 12:05 PM
Purple Biotech To Present New Preclinical Data From CAPTN-3 Platform Of Conditionally Activated Tri-Specific Antibodies At ESMO-IO 2025 Annual Congress
📈 PositiveBenzinga•Dec 4, 2025, 12:10 PM
Purple Biotech's TyrNovo Has Been Granted European Patent Number EP3750530 Titled "COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER"
📈 PositiveBenzinga•Nov 24, 2025, 08:59 PM
Purple Biotech Q3 EPADS $(0.29) Misses $(0.26) Estimate
📉 NegativeBenzinga•Nov 14, 2025, 01:25 PM
Purple Biotech shares are trading higher after the company achieved a commercially viable yield for IM1240, positioning the program for future development.
📈 PositiveBenzinga•Oct 29, 2025, 11:34 AM
Purple Biotech Achieved Commercial Viable Yield For IM1240
📈 PositiveBenzinga•Oct 29, 2025, 11:33 AM
Purple Biotech Receives Nasdaq Non-Compliance Notice
📉 NegativeBenzinga•Oct 20, 2025, 08:01 PM
Purple Biotech Says EU Patent Office Issues Intention To Grant European Patent For Combinations Of IRS/STAT3 Dual Modulators And Anti-Cancer Agents For Treating Cancer
📈 PositiveBenzinga•Sep 10, 2025, 12:07 PM
Purple Biotech shares are trading lower after the company announced the pricing of up to an $18 million public offering.
📉 NegativeBenzinga•Sep 4, 2025, 03:13 PM
Purple Biotech prices $6M public offering, $12M potential via warrants; shares down
📉 NegativeSeeking Alpha•Sep 4, 2025, 01:41 PM
Purple Biotech Prices $6M Public Offering Of ~6M ADSs (or Pre-Funded Warrants) At A Combined Price Of $1.00; Short-Term Warrants To Purchase Up To ~12M ADSs At $1.00, For Up To $12M In Potential Additional Proceeds
➖ NeutralBenzinga•Sep 4, 2025, 01:19 PM
Purple Biotech Unveils Cancer Data On New Tri-Specific Antibody IM1240
📈 PositiveBenzinga•Sep 4, 2025, 11:18 AM
PPBT stock has given up its prior loss. Purple Biotech shares were trading lower.
➖ NeutralBenzinga•Sep 3, 2025, 05:24 PM
Purple Biotech shares are trading lower. The company announced its second CAPTN-3 trispecific antibody, targeting TROP2 in development.
📉 NegativeBenzinga•Sep 3, 2025, 01:17 PM
Purple Biotech Announced Its Second CAPTN-3 Trispecific Antibody, IM1305, Targeting TROP2 In Development, FDA Investigational New Drug Submission Planned For 2026
📈 PositiveBenzinga•Sep 3, 2025, 11:14 AM
Frequently Asked Questions about PPBT
What is PPBT's current stock price?
Purple Biotech Ltd. (PPBT) is currently trading at $0.71 per share. The stock has moved -3.08% today.
What is the analyst price target for PPBT?
No analyst price targets are currently available for this stock.
What sector is Purple Biotech Ltd. in?
Purple Biotech Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PPBT's market cap?
Purple Biotech Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PPBT pay dividends?
No, Purple Biotech Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAKTX
Akari Therapeutics, Plc
$0.26
Mkt Cap: $0.0B
CDT
CDT Equity Inc.
$1.63
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
FOXO
FOXO Technologies Inc.
$0.00
Mkt Cap: $0.0B
MSPR
MSP Recovery, Inc.
$0.20
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SYRS
Syros Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
VINC
Vincerx Pharma, Inc.
$0.01
Mkt Cap: $0.0B
XAGE
Longevity Health Holdings Inc.
$0.43
Mkt Cap: $0.0B
Explore stocks similar to PPBT for comparison